Mean costs, outcomes and incremental cost-effectiveness over a 10-year time-horizon
| Strategy | Mean costs | Cumulative monitoring/ device costs | % with first TE event | % with first major bleed | Mean QALYs | Incremental cost | Incremental QALYs | ICER |
|---|---|---|---|---|---|---|---|---|
| Self-monitoring (50% self-management, 50% self-testing) versus standard care | ||||||||
| Standard monitoring | £7324 | £1269 | 14.2 | 30.2 | 5.479 | – | – | – |
| Self-monitoring | £7326 | £1944 | 11.7 | 31.4 | 5.507 | £2 | 0.028 | £71 |
| Base case—100% self-management versus standard care | ||||||||
| Standard monitoring | £7324 | £1269 | 14.2 | 30.2 | 5.479 | – | – | – |
| Self-management 100% | £6394 | £1717 | 9.2 | 32.7 | 5.535 | −£930 | 0.056 | Dominant |
| Base case—100% self-testing versus standard care | ||||||||
| Standard monitoring | £7324 | £1269 | 14.2 | 30.2 | 5.479 | – | – | – |
| Self-testing 100% | £8258 | £2171 | 14.2 | 30.1 | 5.479 | £934 | 0 | £2 811 298 |
TE, thromboembolic; QALYs, quality adjusted life years; ICER, incremental cost-effectiveness ratio.